中国神经再生研究(英文版)

神经退行性病

1.	Rapamycin reverses ferroptosis by increasing autophagy in MPTP/MPP+-induced models of Parkinson’s disease (2023-05-05)
2.	Long-term radiofrequency electromagnetic fields exposure attenuates cognitive dysfunction in 5×FAD mice by regulating microglial function (2023-05-05)
3.	Exosomes derived from human umbilical cord mesenchymal stem cells alleviate Parkinson’s disease and neuronal damage through inhibition of microglia (2023-03-29)
4.	5-Hydroxytryptamine: a potential therapeutic target in amyotrophic lateral sclerosis (2023-03-07)
5.	Single-nuclei RNA sequencing uncovers heterogenous transcriptional signatures in Parkinson’s disease associated with nuclear receptor-related factor 1 defect (2023-03-07)
6.	Inhibiting 5-hydroxytryptamine receptor 3 alleviates pathological changes of a mouse model of Alzheimer’s disease (2023-03-07)
7.	Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson’s disease (2023-02-27)
8.	Emodin attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis (2023-01-12)
9.	A candidate protective factor in amyotrophic lateral sclerosis: heterogenous nuclear ribonucleoprotein G (2023-01-12)
10.	Overexpression of fibroblast growth factor 13 ameliorates amyloid-β-induced neuronal damage (2023-01-05)
11.	The relationship among amyloid-β deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer’s disease pathological process (2023-01-05)
12.	Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells (2023-01-05)
13.	Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson’s disease (2022-11-01)
14.	Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease (2022-11-01)
15.	Neural progenitor cells derived from fibroblasts induced by small molecule compounds under hypoxia for treatment of Parkinson’s disease in rats (2022-11-01)
16.	TMEM16F may be a new therapeutic target for Alzheimer’s disease (2022-08-29)
17.	The Alzheimer’s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation (2022-07-20)
18.	Lactoferrin modification of berberine nanoliposomes enhances the neuroprotective effects in a mouse model of Alzheimer’s disease (2022-06-17)
19.	DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson’s disease (2022-06-17)
20.	Lamotrigine protects against cognitive deficits, synapse and nerve cell damage, and hallmark neuropathologies in a mouse model of Alzheimer’s disease (2022-06-17)
21.	Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3×Tg-AD mice (2022-06-17)
22.	Dysregulated expression and distribution of Kif5α in neurites of wobbler motor neurons (2022-06-17)
23.	Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimer’s disease (2022-03-10)
24.	Abnormal characterization of dynamic functional connectivity in Alzheimer’s disease (2022-03-10)
25.	Endocannabinoid metabolism and Alzheimer’s disease (2022-03-10)
26.	Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet (2022-03-10)
27.	The blood-brain barrier models to study apolipoprotein E genotypes in Alzheimer’s disease (2022-03-10)
28.	Perspective on the relationship between microbiota dysbiosis and neuroinflammation: probiotics as a treatment option (2022-03-10)
29.	Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis? (2022-03-10)
30.	Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease (2022-03-10)
31.	Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease (2022-03-10)
32.	Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail? (2022-03-10)
33.	Crry silencing alleviates Alzheimer’s disease injury by regulating neuroinflammatory cytokines and the complement system (2022-02-08)
34.	Phosphoinositide-3-kinase regulatory subunit 4 participates in the occurrence and development of amyotrophic lateral sclerosis by regulating autophagy (2022-01-12)
35.	Propagation of TDP-43 proteinopathy in neurodegenerative disorders (2022-01-12)
36.	Vibrotactile coordinated reset stimulation for the treatment of Parkinson’s disease (2022-01-12)
37.	Impact of alpha-synuclein pathology on adult neurogenesis: evidence for multilayered mechanisms (2022-01-12)
38.	Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson’s disease? A discussion of data from the culture dish to the clinic (2022-01-12)
39.	All roads lead to Rome — a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer’s disease (2021-12-17)
40.	Liposome based drug delivery as a potential treatment option for Alzheimer’s disease (2021-12-17)

跳至
页
第1页
共6页
共224条记录